CDK4 and breast cancer: Cytoplasmic cyclin E protein, indicative of low-molecular-weight cyclin E isoforms, is a biomarker of aggressive BC, potential resistance to AIs and CDK4/6i[75,76], and increased sensitivity to capecitabine[136].